Pfizer Announces First Participant Dosed in DAYLIGHT Phase 2 Gene Therapy Trial
Pfizer has announced that the first participant has been dosed in the Phase 2 DAYLIGHT study, which will evaluate the safety and tolerability of the company’s investigational mini-dystrophin gene therapy product (fordadistrogene movaparvovec) in very young…Learn More